Bongers, Mathilda L.; Coupé, Veerle M.H. Coup; Jansma, … - In: PharmacoEconomics 30 (2012) 1, pp. 17-34
assess fully published cost-effectiveness studies comparing the new agents docetaxel, paclitaxel, vinorelbine, gemcitabine … evidence is lacking on superiority of one agent in terms of cost effectiveness. The objective of this systematic review was to …; and docetaxel and pemetrexed were dominated by erlotinib. We found indications of superiority in terms of cost …